Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China
Qun Li , Ye Guo , Junli Xue , Xiaoxiao Ge , Fengjuan Lin , Liqiong Xue , Wei Zhao , Wenbo Tang , Chen Hu , Hongyan Ni , Jing Li , Qingyu Wang , Jun Zhu , Jin Li
Background: HLX07 is a novel humanized anti-EGFR monoclonal antibody. This study aimed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of HLX07 combined with different chemotherapy regimens (chemo-regimens) in patients with advanced solid tumors. Methods: This was a single-center, open-label, dose-escalation phase 1b/2 study. Three fixed-dose chemo-regimens were given together with HLX07: 1) gemcitabine 1000 mg/m2 (on Days 1 and 8) and cisplatin 75 mg/m2 (on Day 1) in 3-week cycles for 4–6 cycles; 2) paclitaxel 80 mg/m2 and carboplatin AUC = 2 (both on Days 1, 8, and 15) in 3-week cycles for 4–6 cycles; and 3) mFOLFOX6 (on Day 1) in 2-week cycles for 6–12 cycles. Patients with metastatic or recurrent advanced solid tumors suitable to be treated with the above chemo-regimens were given HLX07 IV at escalating doses (400, 600, or 800 mg, QW) combined with chemotherapies following BOIN design. The primary endpoints were dose-limiting toxicities (DLTs) and maximum tolerated dose (MTD). Secondary endpoints included safety and preliminary efficacy. Results: As of August 28, 2022, 56 patients were enrolled; 21 received HLX07 with gemcitabine and cisplatin, 21 received HLX07 with paclitaxel and carboplatin (n = 3 for HLX07 400 and 600 mg, n = 15 for HLX07 800 mg for each chemo-regimen), and 14 received HLX07 with mFOLFOX6 (n = 3 for HLX07 400 and 600 mg, n = 8 for HLX07 800 mg). No DLT related to HLX07 was reported. The MTD was not reached. A summary of treatment-emergent adverse events (TEAEs) in each group is shown in Table 1. All patients experienced TEAEs. Grade ≥3 TEAEs were reported by 17 (81.0%), 20 (95.2%), and 12 (85.7%) patients in each chemo-regimen group, respectively. Only 1 (33.3%) patient in the HLX07 400 mg plus paclitaxel and carboplatin group experienced TEAE leading to death (upper gastrointestinal hemorrhage, possibly unrelated to study drugs). Conclusions: HLX07 was safe and well tolerated when combined with chemotherapy in patients with advance solid tumors. Clinical trial information: NCT03577704.
Chemo-regimen | HLX07 dose, mg | TEAE, n (%) | Grade ≥3 TEAE, n (%) | Serious adverse event, n (%) | TEAE leading to death, n (%) | Infusion related reaction, n (%) |
---|---|---|---|---|---|---|
Gemcitabine + cisplatin | 400 (n = 3) | 3 (100) | 2 (66.7) | 0 | 0 | 0 |
600 (n = 3) | 3 (100) | 3 (100) | 0 | 0 | 0 | |
800 (n = 15) | 15 (100) | 12 (80.0) | 7 (46.7) | 0 | 0 | |
All doses (n = 21) | 21 (100) | 17 (81.0) | 7 (33.3) | 0 | 0 | |
Paclitaxel + carboplatin | 400 (n = 3) | 3 (100) | 3 (100) | 2 (66.7) | 1 (33.3) | 0 |
600 (n = 3) | 3 (100) | 3 (100) | 1 (33.3) | 0 | 0 | |
800 (n = 15) | 15 (100) | 14 (93.3) | 7 (46.7) | 0 | 0 | |
All doses (n = 21) | 21 (100) | 20 (95.2) | 10 (47.6) | 1 (4.8) | 0 | |
mFOLFOX6 | 400 (n = 3) | 3 (100) | 2 (66.7) | 0 | 0 | 0 |
600 (n = 3) | 3 (100) | 3 (100) | 1 (33.3) | 0 | 0 | |
800 (n = 8) | 8 (100) | 7 (87.5) | 4 (50.0) | 0 | 0 | |
All doses (n = 14) | 14 (100) | 12 (85.7) | 5 (35.7) | 0 | 0 |
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2023 ASCO Genitourinary Cancers Symposium
First Author: Matt D. Galsky
2023 ASCO Genitourinary Cancers Symposium
First Author: Matt D. Galsky
2024 ASCO Annual Meeting
First Author: John Ebben
2022 ASCO Genitourinary Cancers Symposium
First Author: Parmod Kumar